Phase II trial of weekly docetaxel and carboplatin as first line chemotherapy in advanced or metastatic non small cell lung cancer (NSCLC)

A multicenter, randomized, phase 2 clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum‐sensitive ovarian cancer

“…The predominant docetaxel‐related toxicity is neutropenia. To decrease the incidence of hematologic toxicity, weekly docetaxel, either alone (30‐50 mg/m 2 per week intravenously [iv])16‐22 or in combination (30‐35 mg/m 2 per week iv) with carboplatin (weekly area under the curve [AUC] = 2 or bolus AUC = 5‐6 every 3‐4 weeks) has been evaluated 23‐25. Weekly docetaxel appeared to have similar activity compared with 3‐week administration, with a favorable toxicity profile.…”